Vanguard Group Inc. grew its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 15.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,869,582 shares of the company's stock after purchasing an additional 512,768 shares during the quarter. Vanguard Group Inc. owned approximately 4.56% of Terns Pharmaceuticals worth $21,437,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of TERN. Rhumbline Advisers boosted its stake in Terns Pharmaceuticals by 16.0% in the fourth quarter. Rhumbline Advisers now owns 97,892 shares of the company's stock worth $542,000 after buying an additional 13,479 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Terns Pharmaceuticals by 1.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 154,714 shares of the company's stock valued at $1,290,000 after purchasing an additional 1,994 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Terns Pharmaceuticals by 7.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,207,479 shares of the company's stock valued at $10,072,000 after purchasing an additional 85,617 shares in the last quarter. Savant Capital LLC bought a new position in shares of Terns Pharmaceuticals during the 4th quarter valued at $89,000. Finally, LPL Financial LLC raised its position in Terns Pharmaceuticals by 397.2% in the 4th quarter. LPL Financial LLC now owns 252,325 shares of the company's stock worth $1,398,000 after purchasing an additional 201,575 shares during the period. 98.26% of the stock is owned by hedge funds and other institutional investors.
Terns Pharmaceuticals Stock Performance
NASDAQ:TERN traded up $0.17 during midday trading on Friday, reaching $2.41. 891,657 shares of the stock traded hands, compared to its average volume of 1,516,793. The stock has a market capitalization of $209.95 million, a P/E ratio of -2.04 and a beta of -0.13. The company has a fifty day moving average of $3.15 and a 200 day moving average of $5.05. Terns Pharmaceuticals, Inc. has a 12 month low of $1.87 and a 12 month high of $11.40.
Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.06. On average, analysts predict that Terns Pharmaceuticals, Inc. will post -1.19 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Separately, William Blair reaffirmed a "market perform" rating on shares of Terns Pharmaceuticals in a research note on Friday, March 21st. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $18.38.
View Our Latest Research Report on Terns Pharmaceuticals
Terns Pharmaceuticals Company Profile
(
Free Report)
Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
Recommended Stories
Before you consider Terns Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terns Pharmaceuticals wasn't on the list.
While Terns Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
